These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 33030294)
1. Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy. Santos JL; Cortés VA Obes Rev; 2021 Jan; 22(1):e13114. PubMed ID: 33030294 [TBL] [Abstract][Full Text] [Related]
2. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199 [TBL] [Abstract][Full Text] [Related]
5. A new mutation in the Mancioppi V; Daffara T; Romanisio M; Ceccarini G; Pelosini C; Santini F; Bellone S; Mellone S; Baricich A; Rabbone I; Aimaretti G; Akinci B; Giordano M; Prodam F Front Endocrinol (Lausanne); 2023; 14():1212729. PubMed ID: 37501786 [TBL] [Abstract][Full Text] [Related]
6. Monogenic disorders of obesity and body fat distribution. Chen D; Garg A J Lipid Res; 1999 Oct; 40(10):1735-46. PubMed ID: 10508193 [TBL] [Abstract][Full Text] [Related]
7. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Shastry S; Delgado MR; Dirik E; Turkmen M; Agarwal AK; Garg A Am J Med Genet A; 2010 Sep; 152A(9):2245-53. PubMed ID: 20684003 [TBL] [Abstract][Full Text] [Related]
9. Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy. Simsir IY; Yurekli BS; Polat I; Saygili F; Akinci B Natl Med J India; 2020; 33(5):278-280. PubMed ID: 34213454 [TBL] [Abstract][Full Text] [Related]
10. Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency. Altarejos JY; Pangilinan J; Podgrabinska S; Akinci B; Foss-Freitas M; Neidert AH; Ray Y; Zheng W; Kim S; Kamat V; Huang M; Min S; Mastaitis J; Dominguez-Gutierrez G; Kim JH; Stevis P; Huang T; Zambrowicz B; Olson WC; Godin S; Bradley E; Gewitz AD; Baker M; Hench R; Davenport MS; Chenevert TL; DiPaola F; Yancopoulos GD; Murphy AJ; Herman GA; Musser BJ; Dansky H; Harp J; Gromada J; Sleeman MW; Oral EA; Olenchock BA Sci Transl Med; 2023 Nov; 15(723):eadd4897. PubMed ID: 37992152 [TBL] [Abstract][Full Text] [Related]
11. Rare genetic forms of obesity: From gene to therapy. Clément K; Mosbah H; Poitou C Physiol Behav; 2020 Dec; 227():113134. PubMed ID: 32805220 [TBL] [Abstract][Full Text] [Related]
12. Clinical classification and treatment of congenital and acquired lipodystrophy. Chan JL; Oral EA Endocr Pract; 2010; 16(2):310-23. PubMed ID: 20061300 [TBL] [Abstract][Full Text] [Related]
13. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. Antuna-Puente B; Boutet E; Vigouroux C; Lascols O; Slama L; Caron-Debarle M; Khallouf E; Lévy-Marchal C; Capeau J; Bastard JP; Magré J J Clin Endocrinol Metab; 2010 Mar; 95(3):1463-8. PubMed ID: 20097706 [TBL] [Abstract][Full Text] [Related]
14. Conversations between insulin and bone: Potential mechanism of high bone density in patients with Berardinelli-Seip Congenital Lipodystrophy. Lima JG; Lima NN; Nobrega LH; Jeronimo SM Med Hypotheses; 2016 Dec; 97():94-97. PubMed ID: 27876139 [TBL] [Abstract][Full Text] [Related]
15. When Leptin Is Not There: A Review of What Nonsyndromic Monogenic Obesity Cases Tell Us and the Benefits of Exogenous Leptin. Salum KCR; Rolando JM; Zembrzuski VM; Carneiro JRI; Mello CB; Maya-Monteiro CM; Bozza PT; Kohlrausch FB; da Fonseca ACP Front Endocrinol (Lausanne); 2021; 12():722441. PubMed ID: 34504472 [TBL] [Abstract][Full Text] [Related]
16. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy. Akinci G; Akinci B Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498 [TBL] [Abstract][Full Text] [Related]
17. Approach to the Patient With Lipodystrophy. Fourman LT; Grinspoon SK J Clin Endocrinol Metab; 2022 May; 107(6):1714-1726. PubMed ID: 35137140 [TBL] [Abstract][Full Text] [Related]
18. [Genetics of congenital lipodystrophies]. Buffet A; Lombes M; Caron P Ann Endocrinol (Paris); 2015 Oct; 76(6 Suppl 1):S2-9. PubMed ID: 26776286 [TBL] [Abstract][Full Text] [Related]
19. Short-term time-restricted feeding during the resting phase is sufficient to induce leptin resistance that contributes to development of obesity and metabolic disorders in mice. Oishi K; Hashimoto C Chronobiol Int; 2018 Oct; 35(11):1576-1594. PubMed ID: 30084652 [TBL] [Abstract][Full Text] [Related]
20. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Shimomura I; Hammer RE; Ikemoto S; Brown MS; Goldstein JL Nature; 1999 Sep; 401(6748):73-6. PubMed ID: 10485707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]